Cargando…

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia

In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control by BCR::ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance against these TKI may occur. We identified the epigenetic reader BRD4 and its downstream‐effector MYC as growth regulato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peter, Barbara, Eisenwort, Gregor, Sadovnik, Irina, Bauer, Karin, Willmann, Michael, Rülicke, Thomas, Berger, Daniela, Stefanzl, Gabriele, Greiner, Georg, Hoermann, Gregor, Keller, Alexandra, Wolf, Dominik, Čulen, Martin, Winter, Georg E., Hoffmann, Thomas, Schiefer, Ana‐Iris, Sperr, Wolfgang R., Zuber, Johannes, Mayer, Jiří, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546315/ https://www.ncbi.nlm.nih.gov/pubmed/35794848 http://dx.doi.org/10.1002/ajh.26650

Ejemplares similares

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects
por: Culen, Martin, et al.
Publicado: (2016)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

BRD4: A BET(ter) target for the treatment of AML?
por: Valent, Peter, et al.
Publicado: (2014)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
por: Blatt, Katharina, et al.
Publicado: (2016)

In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2020)

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
por: Gleixner, Karoline V., et al.
Publicado: (2017)

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2019)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

MYC protein stability is negatively regulated by BRD4
por: Devaiah, Ballachanda N., et al.
Publicado: (2020)

Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms
por: Willmann, Michael, et al.
Publicado: (2018)

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
por: Coudé, Marie-Magdelaine, et al.
Publicado: (2015)

Transcriptional regulation of BRD7 expression by Sp1 and c-Myc
por: Liu, Huaying, et al.
Publicado: (2008)

Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal
por: Willmann, Michael, et al.
Publicado: (2021)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
por: Valent, Peter, et al.
Publicado: (2019)

Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
por: Byrgazov, Konstantin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vutohadvah7hu64jffbf27s11i